VBL Therapeutics has developed the Lecinoxoids, a novel class of orally-available anti-inflammatory small molecules. 

Lecinoxoids mimic the structure of native phospholipid molecules that regulate the inflammatory process in the body. The lead candidate from the lecinoxoids platform, VB-201, is an oral small molecule that has been administered to more than 600 patients and is Phase-2 ready. 

Lecinoxoids have demonstrated promising pre-clinical results in NASH and renal fibrosis models.